;PMID: 12963998
;source_file_2945.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:42..119] = [t:42..119]
;2)section:[e:123..246] = [t:123..246]
;3)section:[e:250..356] = [t:250..356]
;4)sentence:[e:360..542] = [t:360..542]
;5)sentence:[e:543..613] = [t:543..613]
;6)sentence:[e:614..699] = [t:614..699]
;7)sentence:[e:700..811] = [t:700..811]
;8)sentence:[e:812..863] = [t:812..863]
;9)sentence:[e:864..1070] = [t:864..1070]
;10)sentence:[e:1072..1156] = [t:1072..1156]
;11)sentence:[e:1157..1338] = [t:1157..1338]
;12)sentence:[e:1339..1468] = [t:1339..1468]
;13)section:[e:1472..1508] = [t:1472..1508]

;section 0 Span:0..36
;Int J Oncol.  2003 Oct;23(4):1151-7.
(SEC
  (FRAG (NNP:[0..3] Int) (NNP:[4..5] J) (NNP:[6..11] Oncol) (.:[11..12] .)
        ('':[14..18] 2003) (CC:[19..26] Oct;23-LRB-) (CD:[26..27] 4)
        (-RRB-:[27..28] -RRB-) (::[28..29] :) (CD:[29..33] 1151)
        (HYPH:[33..34] -) (CD:[34..36] 7.)))

;sentence 1 Span:42..119
;Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid
;tumors.
;[57..65]:gene-rna:"p16INK4A"
;[67..73]:gene-rna:"p14ARF"
;[78..86]:gene-rna:"p15INK4B"
;[96..105]:malignancy-developmental-state:"pediatric"
;[106..118]:malignancy-type:"solid tumors"
(SENT
  (NP-HLN
    (NP (NNS:[42..53] Aberrations))
    (PP (IN:[54..56] of)
      (NP
        (NP (NN:[57..65] p16INK4A)
          (NML-1 (-NONE-:[65..65] *P*)))
        (,:[65..66] ,)
        (NP (NN:[67..73] p14ARF)
          (NML-1 (-NONE-:[73..73] *P*)))
        (CC:[74..77] and)
        (NP (NN:[78..86] p15INK4B)
          (NML-1 (NNS:[87..92] genes)))))
    (PP-LOC (IN:[93..95] in)
      (NP (JJ:[96..105] pediatric)
         (JJ:[106..111] solid) (NNS:[112..118] tumors)))
    (.:[118..119] .)))

;section 2 Span:123..246
;Obana K, Yang HW, Piao HY, Taki T, Hashizume K, Hanada R, Yamamoto K, Tanaka
;Y,  Toyoda Y, Takita J, Tsuchida Y, Hayashi Y.
(SEC
  (FRAG (NNP:[123..128] Obana) (NNP:[129..131] K,) (NNP:[132..136] Yang)
        (NNP:[137..139] HW) (,:[139..140] ,) (NNP:[141..145] Piao)
        (NNP:[146..148] HY) (,:[148..149] ,) (NNP:[150..154] Taki)
        (NNP:[155..156] T) (,:[156..157] ,) (NNP:[158..167] Hashizume)
        (NNP:[168..170] K,) (NNP:[171..177] Hanada) (NNP:[178..179] R)
        (,:[179..180] ,) (NNP:[181..189] Yamamoto) (NNP:[190..192] K,)
        (NNP:[193..199] Tanaka) (NNP:[200..201] Y) (,:[201..202] ,)
        (NNP:[204..210] Toyoda) (NNP:[211..212] Y) (,:[212..213] ,)
        (NNP:[214..220] Takita) (NNP:[221..223] J,) (NNP:[224..232] Tsuchida)
        (NNP:[233..234] Y) (,:[234..235] ,) (NNP:[236..243] Hayashi)
        (NNP:[244..245] Y) (.:[245..246] .)))

;section 3 Span:250..356
;Department of Pediatric Surgery, Graduate School of Medicine, University of 
;Tokyo, Tokyo 113-8655, Japan.
(SEC
  (FRAG (NNP:[250..260] Department) (IN:[261..263] of)
        (NNP:[264..273] Pediatric) (NNP:[274..281] Surgery) (,:[281..282] ,)
        (NNP:[283..291] Graduate) (NNP:[292..298] School) (IN:[299..301] of)
        (NNP:[302..310] Medicine) (,:[310..311] ,) (NNP:[312..322] University)
        (IN:[323..325] of) (NNP:[327..332] Tokyo) (,:[332..333] ,)
        (NNP:[334..339] Tokyo) (CD:[340..348] 113-8655) (,:[348..349] ,)
        (NNP:[350..355] Japan) (.:[355..356] .)))

;sentence 4 Span:360..542
;Expression of the p16INK4A (p16), p15INK4B (p15), and p14ARF genes, located
;at  9p21, was examined in pediatric neuroblastoma (NB), Ewing's sarcoma (ES),
;and  rhabdomyosarcoma (RMS).
;[378..386]:gene-rna:"p16INK4A"
;[388..391]:gene-rna:"p16"
;[394..402]:gene-rna:"p15INK4B"
;[404..407]:gene-rna:"p15"
;[414..420]:gene-rna:"p14ARF"
;[440..444]:variation-location:"9p21"
;[462..471]:malignancy-developmental-state:"pediatric"
;[472..485]:malignancy-type:"neuroblastoma"
;[487..489]:malignancy-type:"NB"
;[492..507]:malignancy-type:"Ewing's sarcoma"
;[509..511]:malignancy-type:"ES"
;[519..535]:malignancy-type:"rhabdomyosarcoma"
;[537..540]:malignancy-type:"RMS"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[360..370] Expression))
      (PP (IN:[371..373] of)
        (NP
          (NP (DT:[374..377] the)
            (NML
              (NML
                (NML
                  (NML (NN:[378..386] p16INK4A))
                  (NML (-LRB-:[387..388] -LRB-) (NN:[388..391] p16)
                       (-RRB-:[391..392] -RRB-)))
                (NML-2 (-NONE-:[392..392] *P*)))
              (,:[392..393] ,)
              (NML
                (NML
                  (NML (NN:[394..402] p15INK4B))
                  (NML (-LRB-:[403..404] -LRB-) (NN:[404..407] p15)
                       (-RRB-:[407..408] -RRB-)))
                (NML-2 (-NONE-:[408..408] *P*)))
              (,:[408..409] ,) (CC:[410..413] and)
              (NML (NN:[414..420] p14ARF)
                (NML-2 (NNS:[421..426] genes)))))
          (,:[426..427] ,)
          (VP (VBN:[428..435] located)
            (NP (-NONE-:[435..435] *))
            (PP-LOC (IN:[436..438] at)
              (NP (NN:[440..444] 9p21)))))))
    (,:[444..445] ,)
    (VP (VBD:[446..449] was)
      (VP (VBN:[450..458] examined)
        (NP-1 (-NONE-:[458..458] *))
        (PP (IN:[459..461] in)
          (NP
            (NP
              (NP (JJ:[462..471] pediatric) (NN:[472..485] neuroblastoma))
              (NP (-LRB-:[486..487] -LRB-) (NN:[487..489] NB)
                  (-RRB-:[489..490] -RRB-)))
            (,:[490..491] ,)
            (NP
              (NP
                (NP (NNP:[492..497] Ewing) (POS:[497..499] 's))
                (NN:[500..507] sarcoma))
              (NP (-LRB-:[508..509] -LRB-) (NN:[509..511] ES)
                  (-RRB-:[511..512] -RRB-)))
            (,:[512..513] ,) (CC:[514..517] and)
            (NP
              (NP (NN:[519..535] rhabdomyosarcoma))
              (NP (-LRB-:[536..537] -LRB-) (NN:[537..540] RMS)
                  (-RRB-:[540..541] -RRB-)))))))
    (.:[541..542] .)))

;sentence 5 Span:543..613
;p16 expression was absent in 4 of 5 ESs, and 2 of these  4 cases died.
;[543..546]:gene-rna:"p16"
;[579..582]:malignancy-type:"ESs"
(SENT
  (S
    (S
      (NP-SBJ (NN:[543..546] p16) (NN:[547..557] expression))
      (VP (VBD:[558..561] was)
        (ADJP-PRD (JJ:[562..568] absent)
          (PP-LOC (IN:[569..571] in)
            (NP
              (NP (CD:[572..573] 4))
              (PP (IN:[574..576] of)
                (NP (CD:[577..578] 5) (NNS:[579..582] ESs))))))))
    (,:[582..583] ,) (CC:[584..587] and)
    (S
      (NP-SBJ
        (NP (CD:[588..589] 2))
        (PP (IN:[590..592] of)
          (NP (DT:[593..598] these) (CD:[600..601] 4) (NNS:[602..607] cases))))
      (VP (VBD:[608..612] died)))
    (.:[612..613] .)))

;sentence 6 Span:614..699
;p16 expression was reduced or absent in 10 of 12 RMSs, and 4 of  these 10
;cases died.
;[614..617]:gene-rna:"p16"
;[663..667]:malignancy-type:"RMSs"
(SENT
  (S
    (S
      (NP-SBJ-1 (NN:[614..617] p16) (NN:[618..628] expression))
      (VP (VBD:[629..632] was)
        (UCP
          (VP (VBN:[633..640] reduced)
            (NP-1 (-NONE-:[640..640] *)))
          (CC:[641..643] or)
          (ADJP-PRD (JJ:[644..650] absent))
          (PP-LOC (IN:[651..653] in)
            (NP
              (NP (CD:[654..656] 10))
              (PP (IN:[657..659] of)
                (NP (CD:[660..662] 12) (NNS:[663..667] RMSs))))))))
    (,:[667..668] ,) (CC:[669..672] and)
    (S
      (NP-SBJ
        (NP (CD:[673..674] 4))
        (PP (IN:[675..677] of)
          (NP (DT:[679..684] these) (CD:[685..687] 10) (NNS:[688..693] cases))))
      (VP (VBD:[694..698] died)))
    (.:[698..699] .)))

;sentence 7 Span:700..811
;These results suggested the possibility that p16 expression  was associated
;with the progression of ES and RMS.
;[745..748]:gene-rna:"p16"
;[800..802]:malignancy-type:"ES"
;[807..810]:malignancy-type:"RMS"
(SENT
  (S
    (NP-SBJ (DT:[700..705] These) (NNS:[706..713] results))
    (VP (VBD:[714..723] suggested)
      (NP
        (NP (DT:[724..727] the) (NN:[728..739] possibility))
        (SBAR (IN:[740..744] that)
          (S
            (NP-SBJ-1 (NN:[745..748] p16) (NN:[749..759] expression))
            (VP (VBD:[761..764] was)
              (VP (VBN:[765..775] associated)
                (NP-1 (-NONE-:[775..775] *))
                (PP-CLR (IN:[776..780] with)
                  (NP
                    (NP (DT:[781..784] the) (NN:[785..796] progression))
                    (PP (IN:[797..799] of)
                      (NP (NN:[800..802] ES) (CC:[803..806] and)
                          (NN:[807..810] RMS)))))))))))
    (.:[810..811] .)))

;sentence 8 Span:812..863
;There has been no previous  report on p14ARF in NB.
;[850..856]:gene-rna:"p14ARF"
;[860..862]:malignancy-type:"NB"
(SENT
  (S
    (NP-SBJ (EX:[812..817] There))
    (VP (VBZ:[818..821] has)
      (VP (VBN:[822..826] been)
        (NP-PRD
          (NP (DT:[827..829] no) (JJ:[830..838] previous) (NN:[840..846] report))
          (PP (IN:[847..849] on)
            (NP (NN:[850..856] p14ARF))))
        (PP (IN:[857..859] in)
          (NP (NN:[860..862] NB)))))
    (.:[862..863] .)))

;sentence 9 Span:864..1070
;Our investigation might indicate that abnormal  expression of the p16 and
;p14ARF was associated with a poor prognosis in NB,  although in some cases of
;NB normal p16 and abnormal p14ARF expression was seen.
;[930..933]:gene-rna:"p16"
;[938..944]:gene-rna:"p14ARF"
;[985..987]:malignancy-type:"NB"
;[1016..1018]:malignancy-type:"NB"
;[1026..1029]:gene-rna:"p16"
;[1043..1049]:gene-rna:"p14ARF"
(SENT
  (S
    (NP-SBJ (PRP$:[864..867] Our) (NN:[868..881] investigation))
    (VP (MD:[882..887] might)
      (VP (VB:[888..896] indicate)
        (SBAR (IN:[897..901] that)
          (S
            (NP-SBJ-1
              (NP (JJ:[902..910] abnormal) (NN:[912..922] expression))
              (PP (IN:[923..925] of)
                (NP
                  (NP (DT:[926..929] the) (NN:[930..933] p16))
                  (CC:[934..937] and)
                  (NP (NN:[938..944] p14ARF)))))
            (VP (VBD:[945..948] was)
              (VP (VBN:[949..959] associated)
                (NP-1 (-NONE-:[959..959] *))
                (PP-CLR (IN:[960..964] with)
                  (NP (DT:[965..966] a) (JJ:[967..971] poor)
                      (NN:[972..981] prognosis)))
                (PP (IN:[982..984] in)
                  (NP (NN:[985..987] NB)))
                (,:[987..988] ,)
                (SBAR-ADV (IN:[990..998] although)
                  (S
                    (PP (IN:[999..1001] in)
                      (NP
                        (NP (DT:[1002..1006] some) (NNS:[1007..1012] cases))
                        (PP (IN:[1013..1015] of)
                          (NP (NN:[1016..1018] NB)))))
                    (NP-SBJ-3
                      (NP (JJ:[1019..1025] normal) (NN:[1026..1029] p16)
                        (NML-2 (-NONE-:[1029..1029] *P*)))
                      (CC:[1030..1033] and)
                      (NP (JJ:[1034..1042] abnormal) (NN:[1043..1049] p14ARF)
                        (NML-2 (NN:[1050..1060] expression))))
                    (VP (VBD:[1061..1064] was)
                      (VP (VBN:[1065..1069] seen)
                        (NP-3 (-NONE-:[1069..1069] *))))))))))))
    (.:[1069..1070] .)))

;sentence 10 Span:1072..1156
;These findings suggest an important role of p14ARF gene in the tumorigenesis
;of  NB.
;[1116..1122]:gene-rna:"p14ARF"
;[1153..1155]:malignancy-type:"NB"
(SENT
  (S
    (NP-SBJ (DT:[1072..1077] These) (NNS:[1078..1086] findings))
    (VP (VBP:[1087..1094] suggest)
      (NP
        (NP (DT:[1095..1097] an) (JJ:[1098..1107] important)
            (NN:[1108..1112] role))
        (PP (IN:[1113..1115] of)
          (NP (NN:[1116..1122] p14ARF) (NN:[1123..1127] gene))))
      (PP (IN:[1128..1130] in)
        (NP
          (NP (DT:[1131..1134] the) (NN:[1135..1148] tumorigenesis))
          (PP (IN:[1149..1151] of)
            (NP (NN:[1153..1155] NB))))))
    (.:[1155..1156] .)))

;sentence 11 Span:1157..1338
;The different incidence of expression of the p16, p15, and p14ARF genes in 
;these 3 tumor types may reflect differences of the molecular process through 
;which the 3 tumors develop.
;[1202..1205]:gene-rna:"p16"
;[1207..1210]:gene-rna:"p15"
;[1216..1222]:gene-rna:"p14ARF"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1157..1160] The) (JJ:[1161..1170] different)
          (NN:[1171..1180] incidence))
      (PP (IN:[1181..1183] of)
        (NP
          (NP (NN:[1184..1194] expression))
          (PP (IN:[1195..1197] of)
            (NP (DT:[1198..1201] the)
              (NML
                (NML (NN:[1202..1205] p16)
                  (NML-1 (-NONE-:[1205..1205] *P*)))
                (,:[1205..1206] ,)
                (NML (NN:[1207..1210] p15)
                  (NML-1 (-NONE-:[1210..1210] *P*)))
                (,:[1210..1211] ,) (CC:[1212..1215] and)
                (NML (NN:[1216..1222] p14ARF)
                  (NML-1 (NNS:[1223..1228] genes))))))))
      (PP (IN:[1229..1231] in)
        (NP (DT:[1233..1238] these) (CD:[1239..1240] 3) (NN:[1241..1246] tumor)
            (NNS:[1247..1252] types))))
    (VP (MD:[1253..1256] may)
      (VP (VB:[1257..1264] reflect)
        (NP
          (NP (NNS:[1265..1276] differences))
          (PP (IN:[1277..1279] of)
            (NP
              (NP (DT:[1280..1283] the) (JJ:[1284..1293] molecular)
                  (NN:[1294..1301] process))
              (SBAR
                (WHPP-2 (IN:[1302..1309] through)
                  (WHNP (WDT:[1311..1316] which)))
                (S
                  (NP-SBJ (DT:[1317..1320] the) (CD:[1321..1322] 3)
                          (NNS:[1323..1329] tumors))
                  (VP (VBP:[1330..1337] develop)
                    (PP-2 (-NONE-:[1337..1337] *T*))))))))))
    (.:[1337..1338] .)))

;sentence 12 Span:1339..1468
;Our results suggest that abnormal expression of the  p16 and/or p14ARF may be
;associated with a poor prognosis in these 3 tumors.
;[1392..1395]:gene-rna:"p16"
;[1403..1409]:gene-rna:"p14ARF"
(SENT
  (S
    (NP-SBJ (PRP$:[1339..1342] Our) (NNS:[1343..1350] results))
    (VP (VBP:[1351..1358] suggest)
      (SBAR (IN:[1359..1363] that)
        (S
          (NP-SBJ-1
            (NP (JJ:[1364..1372] abnormal) (NN:[1373..1383] expression))
            (PP (IN:[1384..1386] of)
              (NP (DT:[1387..1390] the) (NN:[1392..1395] p16)
                  (CC:[1396..1402] and/or) (NN:[1403..1409] p14ARF))))
          (VP (MD:[1410..1413] may)
            (VP (VB:[1414..1416] be)
              (VP (VBN:[1417..1427] associated)
                (NP-1 (-NONE-:[1427..1427] *))
                (PP-CLR (IN:[1428..1432] with)
                  (NP (DT:[1433..1434] a) (JJ:[1435..1439] poor)
                      (NN:[1440..1449] prognosis)))
                (PP (IN:[1450..1452] in)
                  (NP (DT:[1453..1458] these) (CD:[1459..1460] 3)
                      (NNS:[1461..1467] tumors)))))))))
    (.:[1467..1468] .)))

;section 13 Span:1472..1508
;PMID: 12963998 [PubMed - in process]
(SEC
  (FRAG (NNP:[1472..1476] PMID) (::[1476..1477] :) (CD:[1478..1486] 12963998)
        (NN:[1487..1488] -LSB-) (NNP:[1488..1494] PubMed) (::[1495..1496] -)
        (IN:[1497..1499] in) (NN:[1500..1507] process) (.:[1507..1508] -RSB-)))
